|
Molecular
Link between Inflammation and Cancer Discovered
01/26/07
Normal
dialogue between cell defense and development (left) and
chronic inflammation leading to hyperactive developmental
signaling that may promote cancer (right).
Credit:
Alexander Hoffmann, UCSD
|
A team led by biochemists
at the University of California, San Diego has found what could
be a long-elusive mechanism through which inflammation can
promote cancer. The findings may provide a new approach for
developing cancer therapies.
The study, published in the
January 26 issue of the journal Cell,
shows that what scientists thought were two distinct processes in
cells—the cells’ normal development and the cells’
response to dangers such as invading organisms—are actually
linked. The researchers, who were also from the Salk Institute
for Biological Studies and the La Jolla Institute for Allergy and
Immunology, say that the linkage of these two processes may
explain why cancer, which is normal growth and development gone
awry, can result from chronic inflammation, which is an
out-of-control response to danger.
“Although there is plenty
of evidence that chronic inflammation can promote cancer, the
cause of this relationship is not understood,” said
Alexander Hoffmann, an assistant professor of chemistry and
biochemistry at U.C. San Diego, who led the study. “We have
identified a basic cellular mechanism that we think may be
linking chronic inflammation and cancer.”
Cellular defense is a rapid
process compared to cellular development, just as a state’s
response to terrorist threats is swifter than the construction of
new infrastructure. However, in both settings, safeguarding
against threats and building structures have certain steps in
common and require similar types of workers, or molecules.
Hoffmann referred to the
parallel sets of steps in cellular defense and development as
“mirror image pathways.” His team showed that these
pathways are not distinct from one another because they are
linked by a protein called p100. They found that inflammation
leads to an increase in p100, but that p100 is also used in
certain steps in development. Therefore p100 allows communication
between inflammation and development.
A small amount of dialogue
between inflammation and development is beneficial, say the
researchers, akin to how information from anti-terrorism efforts
could be useful to crews building the state’s
infrastructure. On the other hand, the constant influence of
defense processes on development is detrimental.
“Studies with animals
have shown that a little inflammation is necessary for the normal
development of the immune system and other organ systems,”
explained Hoffmann. “We discovered that the protein p100
provides the cell with a way in which inflammation can influence
development. But there can be too much of a good thing. In the
case of chronic inflammation, the presence of too much p100 may
overactivate the developmental pathway, resulting in cancer.”
In the paper, the researchers
propose that thinking of the processes of defense and development
as part of a single large system “represents an opportunity
for therapeutic intervention.” For example, it might be
easier to break the link between inflammation and cancer by
targeting the developmental pathway, rather than the inflammation
pathway.
“Many of the
developmental signals that cells use are sent outside the cell,
so they should be easier to block with drugs than inflammation
signals, which tend to be confined within cells,” said
Hoffmann. “It’s more challenging to design drugs that
will enter cells.”
Because the molecules that play
a role in the inflammation and development pathways have been
extensively studied for many years, the researchers say that it
is surprising to find a new molecule that significantly revises
scientists’ understanding about the interactions between
inflammation and development. They credit their discovery to an
approach that combines biochemical techniques and computation.
“Our mathematical model
of inflammation and development includes 98 biochemical
reactions,” said Soumen Basak, a postdoctoral fellow
working with Hoffmann. “ When we ran the model, it
predicted that p100 levels would be elevated for a significant
period of time when the inflammation pathway was stimulated. We
confirmed the prediction using biochemical techniques with cells
in the laboratory.”
“ The finding is exciting
because it means that p100 provides cells with a memory to
inflammatory exposure,” added Basak, who was the first
author on the paper.
Also contributing to the study
were Hana Kim, Jeffrey D. Kearns, Ellen O’Dea, Shannon L.
Werner and Gourisankar Ghosh from U.C. San Diego, Vinay
Tergaonkar and Inder M. Verma from the Salk Institute for
Biological Studies, and Chris A. Benedict and Carl F. Ware from
the La Jolla Institute for Allergy and Immunology.
The study was supported by the
National Institutes of Health, the Leukemia and Lymphoma Society
of America and the American Heart Association.
Source
/ Credit: University of California San Diego / by Sherry
Seethaler
|